Literature DB >> 22261458

Value of PAX8 and WT1 Immunostaining in Confirming the Ovarian Origin of Metastatic Carcinoma in Serous Effusion Specimens.

Lichao Zhao1, Ming Guo, Nour Sneige, Yun Gong.   

Abstract

We evaluated the detection rates of PAX8 and WT1 immunostaining in 68 (45 as cell blocks, 23 as smears) serous effusion specimens that had a cytologic diagnosis of metastatic carcinoma of ovarian origin. Of the cases, 58 (85%) were positive for PAX8, 56 (82%) were positive for WT1, and 64 (94%) were immunoreactive with either or both markers. Detection rates of PAX8 and WT1 were 85% (44/52) and 92% (48/52), respectively, for metastatic serous carcinoma and 100% (5/5) and 20% (1/5), respectively, for metastatic clear cell carcinoma. Detection rates using cell blocks and smears were 91% and 78%, respectively, with PAX8 and 82% and 83%, respectively, with WT1. We concluded that PAX8 and WT1 had comparable overall detection rates in confirming ovarian origin of malignant effusion. The combination of both markers substantially improved the detection rate. Cell blocks and smears can be used for staining, but a cell block is preferred for PAX8 staining.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22261458     DOI: 10.1309/AJCPU0FION3RKKFO

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  8 in total

1.  Initial panel of immunocytochemical markers for identification of primary carcinoma site for effusions and peritoneal washings from women.

Authors:  Gustavo Henrique Soares Takano; Rivadávio Fernandes Amorim; Vânia Moraes Ferreira; Leonora Maciel de Souza Vianna; Tercia Maria Mendes Lousa de Castro; Marcos de Vasconcelos Carneiro; Ísis de Araújo Oliveira; Andrea Barretto Motoyama; Fabiana Pirani Carneiro
Journal:  Int J Clin Exp Pathol       Date:  2022-04-15

2.  Two cases of ovarian carcinoma with endobronchial metastases: Rare presentation.

Authors:  A Upadhyay; V Goel; U Batra; P Goyal; K Dutta; M Aggarwal; D C Doval
Journal:  South Asian J Cancer       Date:  2015 Jul-Sep

3.  Case Report: Mammary and rectal metastases from an ovarian cancer: report of two cases and review of literature.

Authors:  Mounia Amzerin; Camilo Garcia; Claudia Stanciu; Isabelle Veys; Ahmad Awada; Hassan Errihani; Andrea Gombos
Journal:  F1000Res       Date:  2014-10-28

Review 4.  [Value of Cell Block in the Diagnosis of Malignant Pleural Effusion].

Authors:  Fangyuan Cheng; Qian Wang; Diansheng Zhong
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-10-20

Review 5.  Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies.

Authors:  Lindsey A McAlarnen; Prachi Gupta; Reena Singh; Sunila Pradeep; Pradeep Chaluvally-Raghavan
Journal:  Mol Ther Oncolytics       Date:  2022-08-05       Impact factor: 6.311

6.  Cyberknife radiotherapy and anastrozole for the treatment of advanced progressive low-grade papillary serous ovarian carcinoma: A case report.

Authors:  Shandhini Raidoo; Sareena Singh; Raymond Redline; Robert Debernardo
Journal:  Gynecol Oncol Case Rep       Date:  2013-09-21

7.  A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas.

Authors:  Kelsie L Thu; Mahboubeh Papari-Zareei; Victor Stastny; Kai Song; Michael Peyton; Victor D Martinez; Yu-An Zhang; Isabel B Castro; Marileila Varella-Garcia; Hanquan Liang; Chao Xing; Ralf Kittler; Sara Milchgrub; Diego H Castrillon; Heather L Davidson; C Patrick Reynolds; Wan L Lam; Jayanthi Lea; Adi F Gazdar
Journal:  Oncotarget       Date:  2016-06-10

8.  Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.

Authors:  Patrycja Tudrej; Magdalena Olbryt; Ewa Zembala-Nożyńska; Katarzyna A Kujawa; Alexander J Cortez; Anna Fiszer-Kierzkowska; Wojciech Pigłowski; Barbara Nikiel; Magdalena Głowala-Kosińska; Aleksandra Bartkowska-Chrobok; Andrzej Smagur; Wojciech Fidyk; Katarzyna M Lisowska
Journal:  Int J Mol Sci       Date:  2018-07-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.